Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Pushes Stelara Rival Into Phase I

Proposed Ustekinumab Biosimilar Is Competing With Several Other Candidates

Executive Summary

Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.

You may also be interested in...



Samsung Bioepis On The Secrets Of Its Success

Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president talks about what is behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.

Samsung Biologics Sets Out Growth Plans

Samsung Biologics has set out growth plans – including for its Samsung Bioepis biosimilars venture and its CDMO business – after its sales passed the KRW1trn threshold in 2020.

Samsung Bioepis Partners With Yuhan On Korean Adalimumab

Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel